The Transcriptional Enhancer Factor TEF-1 pipeline drugs market research report outlays comprehensive information on the Transcriptional Enhancer Factor TEF-1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transcriptional Enhancer Factor TEF-1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Undisclosed, and Musculoskeletal Disorders which include the indications Solid Tumor, Malignant Mesothelioma, Unspecified, and Fibrosis. It also reviews key players involved in Transcriptional Enhancer Factor TEF-1 targeted therapeutics development with respective active and dormant or discontinued products.
The Transcriptional Enhancer Factor TEF-1 pipeline targets constitutes close to 19 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 1, 1, 6, and 8 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Transcriptional Enhancer Factor TEF-1 overview
Transcriptional enhancer factor TEF-1 (TEAD1) is a transcription factor that plays a key role in the Hippo signaling pathway. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. It a cts by mediating gene expression of YAP1 and WWTR1/TAZ, thereby regulating cell proliferation, migration, and epithelial mesenchymal transition (EMT) induction. It is also involved in cardiac development.
For a complete picture of Transcriptional Enhancer Factor TEF-1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
